Intellectual Property

ICAV follows standard practice in obtaining intellectual property from research institutions and out-licensing agreements with third parties. ICAV negotiates exclusive sublicenses with commercial partners for markets in the developed world while retaining rights to ensure that products will be available to lower- and middle-income countries (LMIs) at affordable prices.

Where commercial sublicenses are executed, institutions will benefit from royalties on sales by the commercial partner. Profits from royalties generated in developed-world markets will be reinvested in ICAV to ensure the sustainability of the ICAV pipeline.

© 2010 International Consortium on Anti-Virals (ICAV) / Consortium International sur les Thérapies Antivirales (CITAV).